PopVax's AI-designed fridge-stable RNA vaccine enters Phase I human trial
SeyoneC · x · 2026-10-11
PopVax India's first fridge-stable RNA vaccine candidate entered a Phase I trial in Australia on Aug 31, after computationally designing 1,300 vaccine constructs, screening 5,000 novel LNP formulations, and building an mRNA-LNP plant capable of a million doses per year at its Hyderabad RNA Foundry.
Related event: PopVax Begins Phase I Trial of Fridge-Stable RNA Vaccine in Australia(2 posts)→
More from Research
- Toronto surgeons train AI to flag safe incision zones in real time during surgery — EricTopol · 2026-10-11
- Mathematician digests OpenAI's number theory results; Hodge papers pulled over sign error — lpachter · 2026-10-11
- SpIDER paper boosts code retrieval for coding agents via semantic search plus code graphs — mangahomanga · 2026-10-11
- CMU professor builds detailed 3D dragon from 27KB of code via Astra — 141_1337 · 2026-10-11
- Claude surfaces hidden planetary system 158 light-years away from public telescope data — DavidmComfort · 2026-10-11
- Diffusion LM Best-Paper Author Dropped Out of Stanford PhD to Join OpenAI — aaron_lou · 2026-10-11